Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group

Failure‐free survival (FFS) and overall survival (OS) rates were found to improve on Intergroup Rhabdomyosarcoma Study (IRS) IV (IRS‐IV) compared with IRS‐III for patients with subset 2 (IRS stage 1, group III nonorbit or stage 3, group I/II) low‐risk embryonal rhabdomyosarcoma with the addition of cyclophosphamide (total cumulative cyclophosphamide dose of 26.4 g/m2) to the combination of vincristine and dactinomycin (VAC). The goal of Children's Oncology Group ARST0331 for subset 2 low‐risk patients was to reduce the total cumulative cyclophosphamide dose without compromising FFS.

[1]  S. Donaldson,et al.  Delayed primary excision with subsequent modification of radiotherapy dose for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee , 2015, International journal of cancer.

[2]  C. Pui,et al.  Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. , 2014, The Lancet. Oncology.

[3]  James R. Anderson,et al.  Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  James R. Anderson,et al.  Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. , 2014 .

[5]  J. Meza,et al.  Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group , 2011, Pediatric blood & cancer.

[6]  James R. Anderson,et al.  Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's O , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  James R. Anderson,et al.  Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  James R. Anderson,et al.  Rhabdomyosarcoma: many similarities, a few philosophical differences. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  H. B. Marsden,et al.  Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  James R. Anderson,et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Diller,et al.  High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood , 2001, Cancer.

[12]  A. Pappo,et al.  Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Gehan,et al.  The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[15]  F. Askin,et al.  Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. , 2007, Blood.

[16]  M. Stevens,et al.  Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Wittes,et al.  Methodologic guidelines for reports of clinical trials. , 1985, Cancer treatment reports.